Outcome of interest | No. of studies | No. of participants | OR/WMD | 95% CI | P-value | I2(%) |
---|---|---|---|---|---|---|
Operative outcomes | ||||||
 Operative time | 7 9–12,14–16 | LLR = 235, OLR= 289 | 1.91 | -15.92, 19.75 | 0.83 | 49 |
 Blood loss | 7 9,11–16 | LLR = 210, OLR= 367 | -173.08 | -297.52, -48.64 | 0.006 | 83 |
 Blood transfusions requirement | 4 10,12,13,15 | LLR = 155, OLR= 278 | 0.35 | 0.20, 0.64 | < 0.001 | 0 |
 Overall morbidity | 8 9–16 | LLR = 270, OLR= 427 | 0.56 | 0.39, 0.82 | 0.003 | 0 |
 Mortality | 8 9–16 | LLR = 268, OLR= 427 | 0.69 | 0.13, 3.75 | 0.67 | 0 |
 Hospital stay | 6 9,10,12,14–16 | LLR = 185, OLR= 204 | -3.54 | -5.12, -1.96 | < 0.001 | 75 |
Oncologic outcomes | ||||||
 Negative surgical margin | 6 9–11,13,14,16 | LLR = 208, OLR= 347 | 2.97 | 1.53, 5.78 | 0.001 | 0 |
 Recurrence | 310,11,15 | LLR = 150, OLR = 185 | 0.68 | 0.41, 1.14 | 0.14 | 0 |
 5-year overall survival | 4 10,12–14 | LLR = 135, OLR= 258 | 1.33 | 0.86, 2.07 | 0.20 | 41 |
 5-year disease-free survival | 4 10,12–14 | LLR = 135, OLR= 258 | 1.48 | 0.89, 2.44 | 0.13 | 45 |